[an error occurred while processing this directive]

高等学校化学研究 ›› 2011, Vol. 27 ›› Issue (5): 836-840.

• Articles • 上一篇    下一篇

Induction of Effective Antitumor Immune Response by Combined Administration of hIL-18 and NDV HN

HUANG Hai-yan1,2,5, MENG Xiang-wei1, LI Xiao1,2,3, SUN Li-li2,4, KAN Shi-fu2,3, LIU Lei1,2, PIAO Bing-guo1,2, YANG Guo-hua1,2, WANG Zhuo-yue2,3, WANG Yu-hang2,3, QI Yan-xin2,3 and JIN Ning-yi2,3*   

  1. 1. Department of Gastroenterology, the First Hospital of Jilin University, Changchun 130021, P. R. China;
    2. Laboratory of Genetic Engineering of PLA,
    3. Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Institute, Academy of Military Medical Sciences, Changchun 130062, P. R. China;
    4. Department of Head and Neck Surgery, Tumor Hospital of Jilin Province, Changchun 130012, P. R. China;
    5. Digestive Internal Medicine, Xuzhou Center Hospital, Xuzhou 221009, P. R. China
  • 收稿日期:2011-01-18 修回日期:2011-03-30 出版日期:2011-09-25 发布日期:2011-09-06
  • 通讯作者: JIN Ning-yi E-mail:ningyik@126.com
  • 基金资助:

    Supported by the Genetically Modified Organisms Breeding Major Projects, China(No.2009ZX08006-002B), the Key Technologies Research and Development Program of Jilin Province, China(No.10ZDGG007) and the Postdoctoral Science Foundation Funded Project of China(No.20100481057).

Induction of Effective Antitumor Immune Response by Combined Administration of hIL-18 and NDV HN

HUANG Hai-yan1,2,5, MENG Xiang-wei1, LI Xiao1,2,3, SUN Li-li2,4, KAN Shi-fu2,3, LIU Lei1,2, PIAO Bing-guo1,2, YANG Guo-hua1,2, WANG Zhuo-yue2,3, WANG Yu-hang2,3, QI Yan-xin2,3 and JIN Ning-yi2,3*   

  1. 1. Department of Gastroenterology, the First Hospital of Jilin University, Changchun 130021, P. R. China;
    2. Laboratory of Genetic Engineering of PLA,
    3. Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Military Veterinary Institute, Academy of Military Medical Sciences, Changchun 130062, P. R. China;
    4. Department of Head and Neck Surgery, Tumor Hospital of Jilin Province, Changchun 130012, P. R. China;
    5. Digestive Internal Medicine, Xuzhou Center Hospital, Xuzhou 221009, P. R. China
  • Received:2011-01-18 Revised:2011-03-30 Online:2011-09-25 Published:2011-09-06
  • Contact: JIN Ning-yi E-mail:ningyik@126.com
  • Supported by:

    Supported by the Genetically Modified Organisms Breeding Major Projects, China(No.2009ZX08006-002B), the Key Technologies Research and Development Program of Jilin Province, China(No.10ZDGG007) and the Postdoctoral Science Foundation Funded Project of China(No.20100481057).

PDF (PC)

摘要： To analyze the antitumor potential and mechanism of action of simultaneous Newcastle disease virus (NDV) hemagglutinin-neuraminidase(HN) and human interleukin 18(hIL-18) gene transfer in C57BL/6 mice with H22 hepatoma，the mouse model with H22 hepatoma was established in C57BL/6 mice, and the antitumor effects of the combined application of NDV HN and hIL-18 were evaluated in vivo. The results show that the growth of established tumors in mice immunized with adenovirus(Ad)-HN in conjunction with Ad-hIL-18 was significantly inhibited compared with that in mice immunized with Ad-HN, Ad-hIL-18 alone, or the empty vector(Ad-mock). Furthermore, the immunization of mice with Ad-HN in conjunction with Ad-hIL-18 elicited strong natural killer activity and H22 tumor-specific cytotoxic T lymphocyte(CTL) responses in vivo. In addition, T cells from the lymph nodes of mice immunized with Ad-hIL-18 or Ad-HN+Ad-hIL-18 secreted high levels of the Th1 cytokine IL-2 and interferon-γ (IFN-γ), indicating that the regression of tumor cells is related to a Th1-type dominant immune response. These results demonstrate that vaccination with NDV HN together with hIL-18 may be a novel and powerful strategy for cancer immunotherapy.

关键词: Newcastle disease virus, Human interleukin 18(hIL-18), Hemagglutinin-neuraminidase(HN), Hepatoma, Antitumor immunity

Abstract: To analyze the antitumor potential and mechanism of action of simultaneous Newcastle disease virus (NDV) hemagglutinin-neuraminidase(HN) and human interleukin 18(hIL-18) gene transfer in C57BL/6 mice with H22 hepatoma，the mouse model with H22 hepatoma was established in C57BL/6 mice, and the antitumor effects of the combined application of NDV HN and hIL-18 were evaluated in vivo. The results show that the growth of established tumors in mice immunized with adenovirus(Ad)-HN in conjunction with Ad-hIL-18 was significantly inhibited compared with that in mice immunized with Ad-HN, Ad-hIL-18 alone, or the empty vector(Ad-mock). Furthermore, the immunization of mice with Ad-HN in conjunction with Ad-hIL-18 elicited strong natural killer activity and H22 tumor-specific cytotoxic T lymphocyte(CTL) responses in vivo. In addition, T cells from the lymph nodes of mice immunized with Ad-hIL-18 or Ad-HN+Ad-hIL-18 secreted high levels of the Th1 cytokine IL-2 and interferon-γ (IFN-γ), indicating that the regression of tumor cells is related to a Th1-type dominant immune response. These results demonstrate that vaccination with NDV HN together with hIL-18 may be a novel and powerful strategy for cancer immunotherapy.

Key words: Newcastle disease virus, Human interleukin 18(hIL-18), Hemagglutinin-neuraminidase(HN), Hepatoma, Antitumor immunity